

# CURRICULUM VITAE

Michael B. Maris, M.D.

## Personal Data

Birth Date: October 9, 1964  
Place of Birth: Steubenville, OH  
Domestic Status: Married, 1 Child  
Citizenship: United States

## Education

1987 B.A. - Biology - West Virginia University, Morgantown, WV  
1995 M.D. - University of Pennsylvania School of Medicine, Philadelphia, PA

## Research and Professional Experience

1988-1991 Research Technician and Coordinator for Basic Science and Clinical Studies Using Optical Spectrometry and Imaging, University of Pennsylvania, Philadelphia, PA  
6/92-8/92 COSTEP Officer in the University of Pennsylvania Community Health Program, Philadelphia, PA  
1995-1998 Internal Medicine Residency, Oregon Health Sciences University, Portland, OR  
7/98-7/01 Senior Fellow in Medical Oncology, University of Washington/ Fred Hutchinson Cancer Research Center, Mentor - Dr. Rainer Storb, Head of Transplantation Biology Program, Seattle, WA  
7/01-6/03 Research Associate, Fred Hutchinson Cancer Research Center - Dr. Rainer Storb, Head of Transplantation Biology Program, Seattle, WA  
7/01-present Acting Instructor of Medicine, University of Washington, Seattle, WA  
7/03-present Associate in Clinical Research, Fred Hutchinson Cancer Research Center - Dr. Rainer Storb, Head of Transplantation Biology Program, Seattle, WA

## Honors and Awards:

Mary Ellis-Bell Award: Significant Research during Medical School  
Honors: Medicine Clerkship, Medicine Subinternship, Pediatric Clerkship, Pediatric Subinternship  
K23-CA92058 Award from the NIH- "Nonmyeloablative Allografting for Hematologic Neoplasms"  
ASH Travel Award 2000, 2001, 2002  
NIH Loan Repayment Award

## Board Certification

1998 Diplomate, Internal Medicine, American Board of Internal Medicine  
1998-date Licensed, Washington State Board of Medical Examiners  
2004 Diplomate, Medical Oncology, American Board of Internal Medicine

## Professional Societies

9/99 American Society of Hematology  
3/00 American Society of Clinical Oncology  
1/02 American Society of Bone Marrow Transplantation  
5/02 Association for Patient-Oriented Research

## Teaching Responsibilities

Mentoring Visiting Physicians  
Attending Physician

## Research Funding

K23-CA92058 "Nonmyeloablative Allografting for Hematologic Neoplasms," 7/1/01 - 6/30/06

## A. Manuscripts in Refereed Journals

1. Smith DS, Levy WJ, **Maris M**, Chance B. Hyperoxia after cardiac arrest in man. J. Cereb. Blood Flow & Metab. 9: S165, 1988.
2. Chance B, **Maris M**, Smith DS, Leigh JS Jr. Quantification of hemoglobin deoxygenation in adult and neonate brain. J. Cereb. Blood Flow & Metab. 9: S580, 1989.

## PUBLICATIONS

### Michael B. Maris, M.D.

3. Chance B, Smith DS, Leigh Jr., **Maris M**, Holtom G. Time resolved spectroscopy of human brain. *Biophys. J.* 55:451, 1989.
4. Smith DS, Levy W, **Maris M**, Chance B. Reperfusion hyperoxia in brain after circulatory arrest in humans. *Anesthesiology* 73:12-19, 1990.
5. Sevick EM, Chance B, Leigh J, Nioka S, **Maris M**. Quantification of Time-and frequency-resolved optical spectra for the determination of tissue oxygenation. *Anal. Biochem.* 195: 330-351, 1991.
6. Chance B, Wang NG, **Maris M**, Nioka S, Sevick E. Quantification of tissue optical characteristics and hemoglobin desaturation by time- and frequency-resolved multi-wavelength spectrophotometry. *Adv. Exp. Med. Biol.* 317: 297-304, 1992.
7. Gratton E, Mantulin WW, vande Ven MJ, Fishkin JB, **Maris M**, Chance B. A novel approach to laser tomography. *Bioimaging* 1: 40-46, 1993.
8. **Maris M**, Gratton E, Maier J, Mantulin W, Chance B. Functional near-infrared imaging of deoxygenated hemoglobin using the frequency domain technique. *Bioimaging* 2: 174-183, 1994.
9. Junghanss,C, Boeckh,M, Carter,RA, Sandmaier,BM, **Maris MB**, Maloney,DG, Chauncey,T, McSweeney,PA, Little,M-T, Corey,L, Storb,R. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. *Blood* 99: 1978-1985, 2002.
10. Junghanss C, Marr KA, Carter RA, Sandmaier BM, **Maris MB**, Maloney DG, Chauncey T, McSweeney PA, Storb R. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared to myeloablative allogeneic hematopoietic stem cell transplantation, a matched control study. *Biology of Blood and Marrow Transplantation* 8:512-520, 2002.
11. Zaucha JM, Mielcarek M, Takatu A, Little M-T, Gooley T, Baker J, Maloney DG, Sandmaier BM, **Maris M**, Chauncey T, Storb R, Torok-Storb B. Engraftment of early erythroid progenitors is not delayed after non-myeloablative major ABO-incompatible haematopoietic stem cell transplantation. *Br J Haematol* 119: 740-750, 2002.
12. Niederwieser D, **Maris M**, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, Maloney DG, Storer B, Lange T, Chauncey T, Deininger M, Pönisch W, Anasetti C, Woolfrey A, Little M-T, Blume KG, McSweeney PA, Storb RF. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. *Blood* 101:1620-1629, 2003
13. Feinstein LC, Sandmaier BM, Hegenbart U, McSweeney PA, Maloney DG, Gooley TA, **Maris MB**, Chauncey TR, Bruno B, Appelbaum FR, Niederwieser DW, Storb RF. Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. *Br J Haematol* 120:281-288, 2003.
14. Fukuda T, Boeckh M, Carter RA, Sandmaier BM, **Maris MB**, Maloney DG, Martin PJ, Storb RF, Marr KA. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. *Blood* 102: 827-833, 2003.
15. Feinstein LC, Sandmaier BM, Maloney DG, **Maris MB**, Gooley TA, Chauncey TR, Hegenbart U, McSweeney PA, Stuart MJ, Forman SJ, Agura EA, Pulsipher MA, Blume KG, Niederwieser DW, Storb RF. Allografting after nonmyeloablative conditioning as a treatment following a failed conventional hematopoietic cell transplant. *Biol Blood Marrow Transplant* 9: 266-272, 2003.
16. Mielcarek M, Martin PJ, Leisenring W, Flowers MED, Maloney DG, Sandmaier BM, **Maris MB**, Storb R. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. *Blood* 102: 756-762, 2003.
17. Kurre P, Pulsipher M, Woolfrey A, **Maris M**, Sandmaier B, Kiem H-P, Storb R. Reduced toxicity and prompt engraftment following minimal conditioning of a patient with fanconi anemia undergoing hematopoietic stem cell transplantation from an HLA-matched unrelated donor. *J Pediatr Hematol Oncol* 25: 581-583, 2003.
18. **Maris M**, Niederwieser D, Sandmaier B, Storer B, Stuart M, Maloney D, Petersdorf E, McSweeney P, Pulsipher M, Woolfrey A, Chauncey T, Agura E, Heimfeld S, Slattery J, Hegenbart U, Anasetti C, Blume K, Storb R. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. *Blood* 102: 2021-2030, 2003.

## PUBLICATIONS

### Michael B. Maris, M.D.

19. **Maris M**, Boeckh M, Storer B, Dawson M, White K, Keng M, Sandmaier B, Maloney D, Storb R, Storek J. Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning. *Exp Hematol* 31: 941-952, 2003.
20. Fukuda T, Hackman RC, Guthrie KA, Sandmaier BM, Boeckh M, **Maris MB**, Maloney DG, Deeg HJ, Martin PJ, Storb RF, Madtes DK. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. *Blood* 102: 2777-2785, 2003.
21. Junghanss C, Storb R, **Maris MB**, Carter RA, Sandmaier BM, Maloney DG, McSweeney PA, Corey L, Boeckh M. Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after nonmyeloablative allogeneic stem cell transplantation. *Brit J Hematol* 123: 662-670, 2003.
22. Bethge WA, Storer BE, **Maris MB**, Flowers MED, Maloney DG, Chauncey TR, Woolfrey AE, Storb R, Sandmaier BM. Relapse or progression after hematopoietic cell transplantation using nonmyeloablative conditioning: effect of interventions on outcome. *Exp Hematol* 31: 974-980, 2003.
23. Hogan WJ, **Maris M**, Storer B, Sandmaier BM, Maloney DG, Schoch HG, Woolfrey AE, Shulman HM, Storb R, McDonald GB. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: A study of 193 patients. *Blood* 103: 78-84, 2004.
24. Bethge WA, Hegenbart U, Stuart MJ, Storer BE, **Maris MB**, Flowers MED, Maloney DG, Chauncey T, Bruno B, Agura E, Forman SJ, Blume KG, Niederwieser D, Storb R, Sandmaier BM. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. *Blood* 103: 790-795, 2004.
25. Diaconescu R, Flowers CR, Storer B, Sorrow ML, **Maris MB**, Maloney DG, Sandmaier BM, Storb R. Morbidity and mortality with nonmyeloablative compared to myeloablative conditioning before hematopoietic cell transplantation from HLA matched related donors. *Blood* 104: 1550-1558, 2004.
26. Sorrow ML, **Maris MB**, Storer B, Sandmaier BM, Diaconescu R, Flowers C, Maloney DG, Storb R. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplant comorbidities. *Blood* 104:961-968, 2004.
27. Parikh CR, Sandmaier BM, Storb RF, Blume KG, Sahebi F, Maloney DG, **Maris MB**, Nieto Y, Edelstein CL, Schrier RW, McSweeney P. Acute renal failure after nonmyeloablative hematopoietic cell transplantation. *Journal of the American Society of Nephrology* 15:1868-1876, 2004.
28. **Maris MB**, Sandmaier BM, Storer BE, Chauncey T, Stuart MJ, Maziarz RT, Agura E, Langston AA, Pulsipher M, Storb R, Maloney DG. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. *Blood* 104: 3535-3542, 2004.
29. Baron F, Baker JE, Storb R, Gooley TA, Sandmaier BM, **Maris MB**, Maloney DG, Heimfeld S, Oparin D, Zellmer E, Radich JP, Grumet FC, Blume KG, Chauncey TR, Little M-T. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. *Blood* 104: 2254-2262, 2004.
30. Flowers MED, Traina F, Storer B, **Maris M**, Bethge WA, Carpenter P, Appelbaum FR, Storb R, Sandmaier BM, Martin PJ. Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning. *Bone Marrow Transplant* 35: 277-282, 2005.
31. Panse JP, Heimfeld S, Guthrie KA, **Maris MB**, Maloney DG, Baril BB, Little M-T, Chauncey TR, Storer BE, Storb R, Sandmaier BM. Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after nonmyeloablative conditioning. *Br J Haematol* 128: 659-667, 2005.
32. Baron F, **Maris MB**, Sandmaier BM, Storer BE, Sorrow M, Diaconescu R, Woolfrey AE, Chauncey TR, Flowers MED, Mielcarek M, Maloney DG, Storb R. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. *J Clin Oncol* (in press)
33. Mielcarek M, Burroughs L, Leisenring W, Diaconescu R, Martin PJ, Sandmaier BM, Maloney DG, **Maris MB**, Chauncey TR, Shizuru JA, Blume KG, Hegenbart U, Niederwieser D, Forman S, Bruno B, Woolfrey A, Storb R. Prognostic relevance of "early-onset" graft-versus-host disease following nonmyeloablative hematopoietic cell transplantation. *Br J Haematol* (in press)

## PUBLICATIONS

### Michael B. Maris, M.D.

34. Baron F, **Maris MB**, Storer BE, Sandmaier BM, Panse JP, Chauncey TR, Sorrow M, Little M-T, Maloney DG, Storb R, Heimfeld S. High doses of transplanted CD34<sup>+</sup> cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. *Leukemia* (in press)
35. Baron F, **Maris MB**, Storer BE, Sandmaier BM, Stuart MJ, McSweeney PA, Radich JP, Pulsipher MA, Agura ED, Chauncey TR, Maloney DG, Shizuru JA, Storb R. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. *Biol Blood Marrow Transplant* (in press)
36. Chien JW, **Maris MB**, Sandmaier BM, Maloney DG, Storb RF, Clark JG. Comparison of lung function after myeloablative and 2 Gy TBI based regimens for hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant*. (in press)
37. Parikh CR, Schrier RW, Storer B, Diaconescu R, Sorrow ML, **Maris MB**, Maloney DG, McSweeney P, Storb R, Sandmaier BM. Comparison of acute renal failure after myeloablative and non-myeloablative hematopoietic cell transplantation. *American Journal of Kidney Diseases*. (in press)
38. Sorrow ML, **Maris MB**, Sandmaier BM, Storer BE, Stuart MJ, Hegenbart U, Agura E, Chauncey TR, Leis J, Pulsipher M, McSweeney P, Radich JP, Bredeson C, Bruno B, Langston A, Loken MR, Al-Ali H, Blume KG, Storb R, Maloney DG. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. *J Clin Oncol*. (in press)

#### B. Invited Editorials and Reviews

1. Mielcarek, M, Sandmaier, BM, Maloney, DG, **Maris M**, McSweeney, PA, Woolfrey, A, Chauncey, T, Feinstein, L, Niederwieser, D, Blume, KG, Forman, S, Torok-Storb, B, Storb, R. Nonmyeloablative hematopoietic cell transplantation: status quo and future perspectives. *J. Clin. Immunol.* 22: 70-74, 2002.
2. Georges GE, **Maris M**, Sandmaier BM, Maloney DG, Feinstein L, Niederwieser D, Shizuru JA, McSweeney PA, Chauncey TR, Agura E, Little M-T, Sahebi F, Hegenbart U, Pulsipher MA, Bruno B, Forman S, Woolfrey AE, Radich JP, Blume KG, Storb R. Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases. *Int J Hematol* 76 (Suppl. 1): 184-189, 2002.
3. Mielcarek, M, Zaucha, JM, Sandmaier, B, Maloney, D, Butrynski, J, **Maris M**, Feinstein, L, Torok-Storb, B, Storb, R. Type of post-grafting immunosuppression after non-myeloablative blood cell transplantation may influence risk of delayed haemolysis due to minor ABO-incompatibility (Letter to the Editor). *Br. J. Haematol.* 116: 500-501, 2002.
4. **Maris M**, Storb R. The transplantation of hematopoietic stem cells after non-myeloablative conditioning: A cellular therapeutic approach to hematologic and genetic diseases. *Immunologic Research* 28: 13-24, 2003.
5. Storb R, Sandmaier BM, Forman S, **Maris M**, Chauncey T, Maloney DG, McSweeney PA, Blume KG, Stuart MJ, Hegenbart U, Sahebi F, Bruno B, Agura E, Little M-T, Niederwieser D. What role for nonmyeloablative conditioning in allogeneic hematopoietic cell transplantation. *Acta Haematologica Polonica* 34 (Suppl. 1): 17-20, 2003.
6. Storb R, Sandmaier BM, Forman S, **Maris M**, Chauncey T, Maloney DG, McSweeney PA, Blume KG, Stuart MJ, Hegenbart U, Sahebi F, Bruno B, Agura E, Little M-T, Niederwieser D. New developments in nonmyeloablative hematopoietic cell transplantation. *Proceedings of the 6th International Stem Cell Workshop 2003* (in press)
7. Sorrow M, **Maris M**, Diaconescu R, Storb R. Do "minitransplantations" have "minitoxicity"? (Letter to the Editor). *Blood*. (in press)

#### C. Other

1. Chance B, Borer E, Evans G, Holtom G, Kent J, **Maris M**, McCully K, Northrop J, Shinkwin, M. Optical and nuclear magnetic resonance studies of hypoxia in human tissue and tumors. In: Galeotti T (ed), *Membranes in Cancer Research*, The New York Academy of Sciences. New York. 1988.
2. Chance B, **Maris M**, Sorge J, Zhang MZ. A phase modulation system for dual wavelength difference spectroscopy of hemoglobin deoxygenation in tissues. In: Lakowicz (ed). *Time-Resolved Laser Spectroscopy in Biochemistry II*. Proc. Soc. Photo Optical Instrum. Eng. 1204: 481-491, 1990.

## PUBLICATIONS

### Michael B. Maris, M.D.

3. Nioka S, Holtom G, Miyaka H, **Maris M**, Chance B. A time resolved spectroscopic (TRS) study of migration of visual to infrared waves in brain tissue in relation to absorption of hemoproteins. In: Goldstick TK, Meyer M, Piiper J (eds). *Adv. Exp. Med. Biol.*, Plenum Press Corp. 277: 71-78, 1990.
4. **Maris M**, Mayevsky A, Sevick E, Chance B. Frequency-domain measurements of changes of optical pathlength during spreading depression in a rodent brain model. In: Chance B (ed), *Proceedings of Time-Resolved Spectroscopy and Imaging of Tissues*. SPIE. Bellingham, WA. 1431:136-148, 1991.
5. Chance B, Hasselgrove J, Wang NG, **Maris M**, Sevick EM. Photon dynamics in tissue imaging. In: *Future Trends in Biomedical Use of Lasers*. Proc SPIE. 1525:68-69, 1991.
6. Haselgrove J, Leigh JS, Yee C, Wang N, **Maris M**, Chance B. Monte carlo and diffusion calculations of photon migration in noninfinite highly scattering media. In: Chance B (ed), *Proceedings of Time-Resolved Spectroscopy and imaging of Tissues*. SPIE. Bellingham, WA. 1431:30-41, 1991.
7. Sevick E, Weng J, **Maris M**, Chance B. Analysis of absorption, scattering, and hemoglobin saturation using phase-modulation spectroscopy. In: Chance, B (ed). *Proceedings of Time-Resolved Spectroscopy and Imaging of Tissues*. SPIE. Bellingham, WA 1431: 274-275, 1991.
8. Sandmaier BM, McSweeney PA, Niederwieser D, Maloney DG, Blume KG, Molina A, Shizuru J, Chauncey T, Georges G, Zaucha JM, **Maris M**, Woolfrey A, Storb R. Post-transplant immunosuppression – canine models and clinical application. In: Giral S, Slavin S (eds): *New Frontiers in Cancer Therapy: Non-myeloablative Stem Cell Transplantation (NST)*. Oxfordshire, UK: Darwin Scientific Publishing Limited, p. 37-43, 2000.
9. Storb R, McSweeney PA, Sandmaier BM, Nash RA, Georges G, Maloney DG, Molina A, **Maris M**, Woolfrey A, Chauncey T, Zaucha M, Blume KG, Shizuru J, Niederwieser D. Nonmyeloablative allogeneic hematopoietic stem cell transplantation. *Hematologica* 85 (Suppl. 2): 85-87, 2000.
10. **Maris MB**, Storb R. Hematopoietic Stem Cell Transplantation. In: Austen KF, Frank MM, Atkinson JP, Cantor H (eds): *Samter's Immunologic Diseases*. Philadelphia, PA: Lippincott Williams & Wilkins, p. 1095-1121, 2001.
11. **Maris M**, Woolfrey A, McSweeney PA, Sandmaier BM, Nash RA, Georges G, Maloney DG, Molina A, Chauncey T, Yu C, Zaucha JM, Blume KG, Shizuru J, Niederwieser D, Storb R. Nonmyeloablative hematopoietic stem cell transplantation: transplantation for the 21st century. *Frontiers in Bioscience* 6:G13-6, 2001.
12. Storb,R, McSweeney,PA, Sandmaier,BM, Nash,RA, Georges,G, Maloney,DG, Molina,A, **Maris M**, Woolfrey,A, Chauncey,T, Zaucha,JM, Blume,KG, Shizuru,J, Niederwieser,D. Nonmyeloablative allografts: from the laboratory to the clinic. In: Dicke,K.A. and Keating,A. (eds.): *Autologous Blood and Marrow Transplantation: Proceedings of the Tenth International Symposium*, Dallas, Texas. Charlottesville, VA: Carden Jennings Publishing, Chapter 7: 315-320, 2001.
13. Feinstein L, Sandmaier B, Maloney D, McSweeney PA, **Maris M**, Flowers C, Radich J, Little M-T, Nash RA, Chauncey T, Woolfrey A, Georges G, Kiem H-P, Zaucha JM, Blume KG, Shizuru J, Niederwieser D, Storb R. Nonmyeloablative hematopoietic cell transplantation: replacing high-dose cytotoxic therapy by the graft-versus-tumor effect. *Ann NY Acad Sci* 938:328-339, 2001
14. **Maris M**, Sandmaier BM, Maloney DG, McSweeney PA, Woolfrey A, Chauncey T, Shizuru J, Niederwieser D, Blume KG, Forman S, Storb R. Non-myeloablative hematopoietic stem cell transplantation. *Transfusion Clinique et Biologique* 8:231-234, 2001.
15. **Maris M**, Storb,R. Outpatient allografting in hematologic malignancies and nonmalignant disorders-applying lessons learned in the canine model to humans. In: Bashey,A. and Ball,E.D. (eds.): *Non-Myeloablative Allogeneic Transplantation*. Boston: Kluwer Academic Publishers, Chapter 8: 149-175, 2002.
16. Storb R, Sandmaier BM, Forman S, **Maris M**, Feinstein L, Chauncey T, Maloney DG, McSweeney PA, Blume KG, Shizuru J, Hegenbart U, Little M-T, Niederwieser D. Haematopoietic cell transplantation from siblings in older patients with haematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. In: *Proceedings of the 5<sup>th</sup> International Stem Cell Workshop: High-Dose Therapy and Transplantation of Haematopoietic Stem Cells (2001)*, Schultze, W. (ed.). Berlin, Germany: Blackwell Publishing Ltd, Chapter 1.1:3-6, 2002.
17. Nash RA, Niederwieser D, McSweeney PA, Sandmaier BM, Georges G, Maloney DG, Feinstein L, **Maris M**, Woolfrey A, Chauncey T, Zaucha JM, Blume KG, Shizuru J, Storb R. Allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen. In: Hiddemann W, Büchner T, Ritter J, Unterhalt M, Haferlach T (eds): *Acute Leukemias IX: Basic Research, Experimental Approaches and Novel Therapies*. Heidelberg, Germany: Sprinter-Verlag, p. 479-482, 2003.

## PUBLICATIONS

### Michael B. Maris, M.D.

18. **Maris MB**, Storb R. Allogeneic hematopoietic cell transplantation as consolidation immunotherapy of cancer after autologous transplantation. *Acta Haematol* (in press)
19. Storb R, Sandmaier BM, Forman S, **Maris M**, Chauncey T, Maloney DG, McSweeney PA, Blume KG, Stuart MJ, Hegenbart U, Sahebi F, Bruno B, Agura E, Little M-T, Niederwieser D. New developments in nonmyeloablative hematopoietic cell transplantation. *Proceedings of the 6th International Stem Cell Workshop 2003*. (in press)

#### D. Abstracts

1. Chance B, Hao L, **Maris M**, Wheatley R. A short magnet NMR study of exercising limbs. *Med. and Sci. in Sports and Exercise*. 21: S68, 1989.
2. **Maris M**, Hao L, Chance B. New approach to limb exercise-short magnet. *Soc. Mag. Reson. In Med. 8rd Ann. Mtg. August 12-18, Amsterdam*. p. 539, 1989.
3. Nioka S, Holton G, Miyake H, **Maris M**, Chance B. Study of photon migration of optical to infrared waves in relation to absorption of hemoproteins in brain tissue. *Intl. Soc. Oxygen Transport to Tissue (ISOTT)*. July 21-24, Gottingen, p. 2A, 1989.
4. Chance B, **Maris M**, Nioka S. Pulse time and phase modulation spectroscopy of hemoglobin and myoglobin in muscle. 10<sup>th</sup> Intl. Biophysics Congress, July 29 - August 3, 1990, Vancouver, Canada.
5. **Maris M**, Chance B, Lenkinski R, Milestone B, Bloch R. Integrated magnetic resonance imaging, magnetic resonance spectroscopy and phase modulated NIR spectroscopic study of squamous cell carcinoma In Vivo. 10<sup>th</sup> Intl. Biophysics Congress, July 29 - August 3, 1990, Vancouver, Canada.
6. Gratton E, Mantulin WW, vande Ven MJ, Fishkin JB, **Maris M**, Chance B. The possibility of a near-infrared optical imaging system using frequency domain methods. *Third Intl. Conf. for Mine through Mind/Brain Science*, August 5-10, 1990. Hamamatsu City, Japan.
7. **Maris M**, Chance B, Lenkinski RE, Milestone BN, Block P. Clinical case study of squamous cell carcinoma using magnetic resonance imaging, magnetic resonance spectroscopy and phase modulated NIR spectroscopy. *Soc. Mag. Reson in Med. 9<sup>th</sup> Ann. Mtg., Aug. 18-24. New York*. 2: 816, 1990.
8. Sevick E, **Maris M**, Chance B. Dynamic and non-invasive detection of hemoglobin saturation in solid tumors. 5<sup>th</sup> Intl. Cancer Cgr. August 1990, Hamburg, Germany.
9. **Maris M**, Sandmaier BM, Niederwieser D, Gooley T, Maloney DG, Shizuru J, McSweeney PA, Little MT, Sahebi S, Forman S, Blume K, Storb R. Comparisons of donor chimerism, graft rejection, and GVHD after hematopoietic stem cell transplants (HSCT) from HLA matched siblings and unrelated donors using conditioning with 2 Gy TBI with and without fludarabine (FLU) (Abstract). *Blood 96 (Part 1): 520a, #2239, 2000*.
10. **Maris M**, Sandmaier BM, Niederwieser D, Maloney DG, McSweeney PA, Chauncey T, Shizuru J, Sahebi S, Blume K, Forman S, Storb R. The effect of donor lymphocyte infusions (DLI) on chimerism and persistent disease after nonmyeloblastic hematopoietic stem cell transplant (HSCT) (Abstract). *Blood (Part 1): 477a, #2053, 2000*.
11. Niederwieser D, **Maris M**, Hegenbart U, Sandmaier B, McSweeney P, Pönisch W, Uharek L, Deininger M, Edelmann J, Kamprath F, Shizuru JA, Blume K, Storb R. Allogeneic unrelated hematopoietic stem cell transplants (HSCT) after conditioning with 2 Gy total body irradiation (TBI), fludarabine (FLU) and a combination of cyclosporine (CSP) and mycophenolate mofetil (MMF) in patients ineligible for conventional transplants (Abstract). *Blood 96 (Part 1): 413a, #1778, 2000*.
12. Cao TM, McSweeney PA, Niederwieser D, Sahebi F, Sandmaier BM, Chauncey TR, **Maris MB**, Forman SJ, Blume KG, Shizuru JA, Storb RF. Non-myeloablative allogeneic hematopoietic cell transplantation (HCT) for patients with myelodysplastic syndromes (MDS) and myeloproliferative disorders (MPD) (Abstract). *Blood 96 (Part 1): 170a, #734, 2000*.
13. Sandmaier BM, Maloney DG, Hegenbart U, McSweeney PA, Shizuru J, Sahebi F, Chauncey T, Radich J, **Maris M**, Molina A, Blume K, Forman S, Niederwieser D, Storb R. Nonmyeloablative conditioning for HLA-identical related allografts for hematologic malignancies (Abstract). *Blood 96 (Part 1): 479a, #2062, 2000*.

## PUBLICATIONS

### Michael B. Maris, M.D.

14. Hegenbart U, Pönisch W, Lange T, Deininger M, Leiblein S, Edelmann J, Kamprath F, Sandmaier B, **Maris M**, McSweeney P, Niederwieser D, Storb R. Successful treatment of severe paroxysmal nocturnal hemoglobinuria (PNH) with allogeneic hematopoietic stem cell transplantation (HSCT) from an unrelated donor using 2 Gy total body irradiation (TBI), fludarabine (FLU) and a combination of cyclosporine (CSP) and mycophenolate mofetil (MMF) (Abstract). *Blood* 96 (Part 1): 419a, #1802, 2000.
15. Little M-T, Baker J, Sandmaier B, **Maris M**, Maloney D, Gooley T, Zellmer E, Heimfeld S, Georges G, Wagner J, Shizuru J, Blume K, Chauncey T, Storb R. Analysis of mixed chimerism in peripheral blood hematopoietic subpopulations from 101 patients after nonmyeloablative hematopoietic stem cell transplant (Abstract). *Blood* 98 (Part 1): 477a, #1992, 2001.
16. Niederwieser D, Petersdorf E, **Maris M**, Hegenbart U, Sandmaier B, Lange T, Poenisch W, Maloney D, Leiblein S, Deininger MW, Al-Ali H, Kliem C, Becker C, Hartung G, Moeckel J, Uharek L, Blume K, Storb R. Successful hematopoietic stem cell transplantation (HSCT) after minimal conditioning in patients with unrelated HLA mismatched donors (Abstract). *Blood* 98 (Part 1): 671a, #2811, 2001.
17. Hegenbart U, Sandmaier B, Lange T, Poenisch W, **Maris M**, Maloney D, Leiblein S, Deininger MW, Al-Ali HK, Kliem C, Becker C, Hartung G, Moeckel J, Chauncey T, Uharek L, Greinix H, Niederwieser D, Storb R. Graft versus leukemia effect after related and unrelated allogeneic hematopoietic stem cell transplants (HSCT) in patients with acute myeloid leukemia (AML) following minimal conditioning (Abstract). *Blood* 98 (Part 1): 672a, #2814, 2001.
18. Mielcarek M, Zaucha JM, Sandmaier B, Maloney D, **Maris M**, Feinstein L, Torok-Storb B, Storb R. Incidence of severe delayed immunehemolysis after minor ABO-incompatible, HLA-matched, related and unrelated donor, non-myeloablative hematopoietic stem cell transplantation (Abstract). *Blood* 98 (Part 1): 778a, #3238, 2001.
19. Deeg HJ, Platzbecker U, Sale GE, Anasetti C, Chauncey T, **Maris M**, Slattery J, Storb R, Appelbaum FR. Allogeneic hematopoietic stem cell transplantation for myelofibrosis (Abstract). *Blood* 98 (Part 1): 856a, #3557, 2001.
20. **Maris M**, Niederwieser D, Sandmaier B, Maloney D, Shizuru J, Petersdorf E, Blume K, Chauncey T, Pulsipher M, McSweeney P, Storer B, Anasetti C, Woolfrey A, Slattery J, Agura E, Little M-T, Hegenbart U, Storb R. Nonmyeloablative hematopoietic stem cell transplants (HSCT) using 10/10 HLA antigen matched unrelated donors (URDs) for patients with advanced hematologic malignancies ineligible for conventional HSCT (Abstract). *Blood* 98 (Part 1): 858a, #3563, 2001.
21. Junghans C, Boeckh M, Carter RA, **Maris MB**, Sandmaier BM, McSweeney P, Maloney D, Corey L, Storb R. CMV infections in nonmyeloablative hematopoietic stem cell transplant (HSCT) recipients- A comparison between related and unrelated donor transplants (Abstract). *Blood* 98 (Part 1): 395a, #1662, 2001.
22. Junghans C, Marr KA, Carter RA, Sandmaier BM, **Maris MB**, Maloney DG, Boeckh M, Chauncey T, McSweeney P, Storb R. Incidence of bacterial and fungal infections after nonmyeloablative compared to myeloablative allogeneic hematopoietic stem cell transplantation (HSCT) (Abstract). *Blood* 98 (Part 1): 479a, #2000, 2001.
23. Feinstein LC, Sandmaier BM, Maloney DG, **Maris MB**, Forman S, Chauncey TR, Shizuru JA, McSweeney PA, Pulsipher M, Blume K, Niederwieser D, Storb R. Nonmyeloablative allogeneic transplantation as a treatment for relapsed hematologic malignancy after a failed conventional autologous or allogeneic transplant (Abstract). *Blood* 98 (Part 1): 855a, #3550, 2001.
24. **Maris MB**, Niederwieser D, Sandmaier B, Maloney D, Shizuru J, Petersdorf E, Blume K, Pulsipher M, McSweeney P, Chauncey T, Storer B, Slattery J, Woolfrey A, Agura E, Hegenbarth U, Feinstein L, Little M, Anasetti C, Storb R. Engraftment of nonmyeloablative hematopoietic stem cell transplants (HSCT) using marrow and PBSC from 10/10 HLA antigen matched unrelated donors (URDs) for patients ineligible for conventional HSCT. *Biol Blood Marrow Transplant* 8: 63, #8, 2002.(Abstract).
25. Feinstein LC, Sandmaier BM, Maloney DG, **Maris MB**, Chauncey TR, Blume K, Shizuru JA, McSweeney PA, Forman S, Agura E, Pulsipher M, Niederweiser D, Storb R. Nonmyeloablative allogeneic transplantation as a salvage therapy following a failed conventional hematopoietic stem cell transplant (HSCT). *Biol Blood Marrow Transplant* 8: 77, #54, 2002.(Abstract).
26. Bethge WA, **Maris MB**, Flowers MED, Maloney DG, Niederwieser D, Chauncey T, Blume KG, Forman SJ, Storb R, Sandmaier BM. Donor lymphocyte infusions after nonmyeloablative marrow transplantation. *Blood* 100 (Part 1): 631a, #2487, 2002.(Abstract).

## PUBLICATIONS

### Michael B. Maris, M.D.

27. Bethge WA, Storer BE, **Maris MB**, Flowers MED, Maloney DG, Storb R, Sandmaier BM. Relapse or progression after nonmyeloablative transplantation: influence of intervention on outcome. *Blood* 100 (Part 1): 176a, #661, 2002.(Abstract).
28. Fukuda T, Boeckh M, Carter RA, Sandmaier BM, **Maris MB**, Maloney DG, Davis C, Storb RF, Martin PJ, Marr KA. Invasive fungal infections in recipients of nonmyeloablative hematopoietic stem cell transplantation: risks and outcomes. *Blood* 100 (Part 1): 625a-626a, #2464, 2002.(Abstract).
29. Fukuda T, Hackman RC, Guthrie KA, Carter RA, Sandmaier BM, **Maris MB**, Maloney DG, Davis C, Marr KA, Boeckh M, Martin PJ, Storb RF, Madtes DK. The intensity of the conditioning regimen outweighs the effect of acute graft-versus-host disease in the pathogenesis of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. *Blood* 100 (Part 1): 413a, #1601, 2002.(Abstract).
30. Giaccone L, **Maris MB**, Sandmaier BM, Slattery JT, Gooley TA, Cole S, Storb R, Nash RA, Georges GE. Mycophenolic acid (MPA) plasma levels in patients following nonmyeloablative HLA-matched unrelated donor hematopoietic cell transplantation (NMURD-HCT). *Blood* 100 (Part 1): 840a-841a, #3318, 2002.(Abstract).
31. Hogan WJ, **Maris M**, Sandmaier BM, Maloney DG, Schoch G, Storer B, Woolfrey AE, Storb R, McDonald GB. Frequency and severity of hepatic injury after conditioning with a nonmyeloablative regimen. *Blood* 100 (Part 1): 412a, #1598, 2002.(Abstract).
32. Little M-T, Baker JE, Sandmaier BM, **Maris MB**, Maloney D, Gooley T, Oparin D, Zellmer E, Mielcarek M, Wagner J, Shizuru J, Blume K, Chauncey T, Storb R. Kinetics of mixed chimerism in peripheral blood hematopoietic subpopulations from 120 patients after nonmyeloablative hematopoietic stem cell transplant. *Blood* 100 (Part 1): 39a, #136, 2002.(Abstract).
33. **Maris MB**, Niederwieser D, Sandmaier BM, Maloney DG, Shizuru J, Petersdorf E, Storer B, Pulsipher M, McSweeney P, Slattery J, Woolfrey A, Agura E, Chauncey T, Little M-T, Hegenbarth U, Anasetti C, Blume K, Storb R. Nonmyeloablative hematopoietic stem cell transplants (NM-HSCT) using 10 HLA antigen matched unrelated donors (URDs) for patients (pts) with advanced hematologic malignancies. *Blood* 100 (Part 1): 76a, #275, 2002.(Abstract).
34. Mielcarek M, Martin PJ, Leisenring W, Flowers MED, Maloney D, Sandmaier B, **Maris M**, Storb R. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. *Blood* 100 (Part 1): 175a, #656, 2002.(Abstract).
35. Hegenbart U, Sandmaier B, Lange T, Poenisch W, **Maris M**, Maloney D, Leiblein S, Al-Ali H, Kliem C, Becker C, Grommisch L, Hartung G, Moeckel J, Chauncey T, Uharek L, Greinix H, Niederwieser D, Blume K, Storb R. Follow-up of allogeneic hematopoietic cell transplantation (HCT) from related and unrelated donors following minimal conditioning in patients with acute myelocytic leukemia (AML). *Blood* 100 (Part 1): 76a, #276, 2002.(Abstract).
36. **Maris MB**, Boeckh M, Dawson M, White K, Sandmaier B, Maloney DG, Storb R, Storek J. Immunologic recovery after nonmyeloablative compared to conventional hematopoietic stem cell transplantation (HSCT) using peripheral blood stem cells (PBSC) from HLA identical sibling donors. *Blood* 100 (Part 1): 843a, #3329, 2002.(Abstract).
37. Diaconescu R, Flowers C, Storer B, Sorrow ML, **Maris M**, Maloney DG, Chauncey T, Sandmaier BM, Storb RF. Morbidity and mortality with nonmyeloablative compared to myeloablative conditioning before hematopoietic cell transplantation from HLA matched related donors. *Blood* 102 (Part 1): 77a-78a, #261, 2003.(Abstract)
38. Flowers MED, Traina F, Storer B, **Maris M**, Bethge W, Carpenter P, Maloney D, Storb R, Sandmaier BM, Martin PJ. Risk factors for severe graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation for treatment of hematological malignancies. *Blood* 102 (Part 1): 152a, #524, 2003.(Abstract)
39. Giaccone L, Sandmaier B, Maloney DG, **Maris M**, Storer B, Chua B, Storb RF, Nash RA, Georges GE. Cyclosporine (CSP) toxicity following nonmyeloablative conditioning (NMC) and allogeneic hematopoietic cell transplantation (HCT). *Blood* 102 (Part 1): 464a, #1693, 2003.(Abstract)
40. Sandmaier BM, **Maris M**, Maloney DG, Gooley TA, Stuart MJ, Hegenbart U, Sahebi F, Chauncey T, Agura E, Bruno B, McSweeney PA, Maziarz R, Pulsipher M, Epner E, Little M-T, Forman SJ, Niederwieser DW, Blume KG, Storb R. Low-dose total body irradiation (TBI) conditioning for hematopoietic cell transplants (HCT) from HLA-matched related (MRD) and unrelated (URD) donors for patients with hematologic malignancies: a five-year experience. *Blood* 102 (Part 1): 78a-79a, #264, 2003.(Abstract)

## PUBLICATIONS

### Michael B. Maris, M.D.

41. Sorror ML, **Maris M**, Storer B, Sandmaier BM, Diaconescu R, Flowers C, Maloney DG, Storb RF. Transplant-related toxicities (TRT) and mortality following HLA-matched unrelated donor hematopoietic cell transplantation (URD-HCT) using nonmyeloablative (NM) compared to myeloablative (M) conditioning: influence of pretransplant comorbidities. *Blood* 102 (Part 1): 78a, #262, 2003.(Abstract)
42. Sorror ML, **Maris M**, Storer B, Sandmaier BM, Maloney DG, Stuart MJ, Pulsipher M, McSweeney PA, Leis JF, Wade JC, Blume KG, Storb RF. Nonmyeloablative (NM) conditioning and allogeneic hematopoietic cell transplantation (HCT) with HLA-matched unrelated donor (URD) for patients (Pts) with chemotherapy-refractory chronic lymphocytic leukemia (CLL). *Blood* 102 (Part 1): 482a, #1757, 2003.(Abstract)
43. Stuart MJ, Cao TM, Sandmaier BM, Hegenbart U, **Maris M**, Agura E, Chauncey TR, Maloney DG, Pulsipher MA, Wong R, Niederwieser DW, Blume KG, Storb RF. Efficacy of non-myeloablative allogeneic transplant for patients with myelodysplastic syndrome (MDS) and myeloproliferative disorders (MPD) (except chronic myelogenous leukemia). *Blood* 102 (Part 1): 185a, #644, 2003.(Abstract)
44. Sorror ML, **Maris MB**, Sandmaier BM, Jain-Stuart M, Storer B, Hegenbart U, McSweeney P, Chauncey T, Bruno B, Wade J, Agura E, Pulsipher M, Leis J, Little M-T, Niederwieser D, Blume K, Storb R, Maloney DG. Treatment of patients (PTS) with chemotherapy-refractory chronic lymphocytic leukemia (CLL) with nonmyeloablative (NM) conditioning and hematopoietic cell transplantation (HCT) from HLA-matched related (MRD) or unrelated donors (URD). *Biol Blood Marrow Transplant* 10 (Suppl. 1): 26-27, #52, 2004.(Abstract)
45. Baron F, **Maris M**, Storer B, Sandmaier B, Panse J, Chauncey T, Sorror M, Little MT, Maloney D, Storb R, Heimfeld S. Higher doses of transplanted CD34+, CD3+ and CD8+ cells are associated with better donor T-cell chimerism and less graft rejection, but not with GVHD after nonmyeloablative conditioning for unrelated hematopoietic cell transplantation. *Blood* 104 (Part 1): 735a, #2753, 2004.(Abstract)
46. Baron F, **Maris MB**, Sandmaier BM, Storer BE, Sorror M, Diaconescu R, Woolfrey AE, Chauncey T, Flowers MED, Mielcarek M, Maloney DG, Storb R. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. *Blood* 104 (Part 1): 56a-57a, #184, 2004.(Abstract)
47. Burroughs LM, **Maris MB**, Sandmaier BM, Leisenring W, Jain Stuart M, Niederwieser D, McSweeney PA, Chauncey T, Maziarz R, Agura E, Little M-T, Blume KG, Storb R, Maloney DG. HLA-matched related (MRD) or unrelated donor (URD) non-myeloablative conditioning and hematopoietic cell transplant (HCT) for patients with advanced Hodgkin disease (HD). *Biol Blood Marrow Transplant* 10 (Suppl. 1): 73-74, #197, 2004.(Abstract)
48. Georges GE, **Maris MB**, Sandmaier BM, Shizuru J, Niederwieser DW, Agura E, Bruno B, McSweeney PA, Storb RF, Maloney DG. Nonmyeloablative unrelated donor hematopoietic cell transplantation (HCT) for patients (pts) with poor risk, relapsed or refractory multiple myeloma. *Blood* 104 (Part 1): 754a, #2756, 2004.(Abstract)
49. Niederwieser DW, Hegenbart U, Sandmaier BM, **Maris MB**, Stuart M, Greinix H, Cordonnier C, Rio B, Gratwohl A, Lange T, Pönisch W, Grommisch L, Storer B, Maloney D, McSweeney P, Chauncey T, Agura E, Blume K, Storb R. Treatment for acute myelogenous leukemia by low dose irradiation based conditioning and hematopoietic cell transplantation from related and unrelated donors. *Blood* 104 (Part 1): 840a, #3074, 2004.(Abstract)
50. Scott BL, **Maris M**, Sandmaier B, Storer B, Chauncey T, Maloney DG, Sorror M, Storb R, Deeg HJ. Myeloablative versus nonmyeloablative hemopoietic cell transplantation (HCT) for patients with myelodysplasia (MDS) or AML with multilineage dysplasia following MDS (tAML). *Blood* 104 (Part 1): 638a, #2320, 2004.(Abstract)
51. Sorror M, **Maris M**, Baron F, Sandmaier B, Maloney D, Storb R, Storer B. A modified hematopoietic cell transplantation (HCT)-specific co-morbidity index. *Blood* 104 (Part 1): 324a-325a, #1146, 2004.(Abstract)
52. Sandmaier BM, Maloney DG, **Maris MB**, Chauncey TR, Pulsipher M, Bethge W, Little M-T, Storb R. Conversion of low donor chimerism following nonmyeloablative conditioning for hematopoietic cell transplantation (HCT) using pentostatin and donor lymphocyte infusion (DLI). *Blood* 104 (Part 1): 57a, #186, 2004.(Abstract)
53. Sorror ML, **Maris MB**, Storb RF, Baron F, Sandmaier BM, Maloney DG, Barry SE. Hematopoietic cell transplantation (HCT)-specific-comorbidity index: a new tool for risk assessment before allogeneic HCT. *Biol Blood Marrow Transplant* 11 (Suppl. 1): 23-24, #67, 2005.(Abstract)

## PUBLICATIONS

Michael B. Maris, M.D.

### E. Presentations

1. Soc. Mag. Reson. In Med. 8<sup>th</sup> Ann. Mtg, August 12-18, 1989, Amsterdam, Netherlands: "New Approach to Limb Exercise-Short Magnet."
2. Soc. Mag. Reson. In Med 9<sup>th</sup> Ann. Mtg., August 18-24, 1990, New York: "Clinical Case Study of Squamous Cell Carcinoma using Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy and Phase Modulated NIR Spectroscopy."
3. SPIE- International Society for Optical Engin., Time-Resolved spectroscopy in Biochem., Los Angeles: Jan. 15-16, 1991: "Frequency-Domain Measurements of Changes of Optical Pathlength during Spreading Depression in a Rodent Brain Model."
4. American Society of Hematology, San Francisco, Dec. 1-5. 2000, "Comparisons of donor chimerism, graft rejection, and GVHD after hematopoietic stem cell transplants (HSCT) from HLA matched siblings and unrelated donors using conditioning with 2 Gy TBI with and without fludarabine (FLU)."
5. American Society of Hematology, San Francisco, Dec. 1-5. 2000, "The effect of donor lymphocyte infusions (DLI) on chimerism and persistent disease after nonmyeloblastic hematopoietic stem cell transplant (HSCT)."
6. American Society of Hematology, Orlando, FL, Dec. 7-11. 2001, "Nonmyeloablative hematopoietic stem cell transplants (HSCT) using 10/10 HLA antigen matched unrelated donors (URDs) for patients with advanced hematologic malignancies ineligible for conventional HSCT."
7. Tandem BMT Meetings, Orlando, FL, Feb. 22-26, 2002, "Engraftment of nonmyeloablative hematopoietic stem cell transplants (HSCT) using marrow and PBSC from 10/10 HLA antigen matched unrelated donors (URDS) for patients ineligible for conventional HSCT."
8. International Society for Cellular Therapy (ISCT) Meeting, Barcelona, Spain, May 25-26, 2002.
9. American Society of Hematology, Philadelphia, PA, Dec. 6-10, 2002, "Nonmyeloablative hematopoietic stem cell transplants (NM-HSCT) using 10 HLA antigen matched unrelated donors (URDS) for patients (Pts) with advanced hematologic malignancies."